Are Vape Pens the New Cigarette? The FDA\u27s Impending Quest to Regulate the E-Cigarette and its Effect on Society\u27s Youth by Morgan, Addison J.
DePaul Journal of Health Care Law 
Volume 21 
Issue 2 Fall 2019 Article 2 
December 2019 
Are Vape Pens the New Cigarette? The FDA's Impending Quest to 
Regulate the E-Cigarette and its Effect on Society's Youth 
Addison J. Morgan 
DePaul University College of Law, amorga30@mail.depaul.edu 
Follow this and additional works at: https://via.library.depaul.edu/jhcl 
 Part of the Health Law and Policy Commons 
Recommended Citation 
Addison J. Morgan, Are Vape Pens the New Cigarette? The FDA's Impending Quest to Regulate the E-
Cigarette and its Effect on Society's Youth, 21 DePaul J. Health Care L. (2019) 
Available at: https://via.library.depaul.edu/jhcl/vol21/iss2/2 
This Article is brought to you for free and open access by the College of Law at Via Sapientiae. It has been 
accepted for inclusion in DePaul Journal of Health Care Law by an authorized editor of Via Sapientiae. For more 
information, please contact digitalservices@depaul.edu. 
ARE VAPE PENS THE NEW CIGARETTE? THE FDA’S IMPENDING QUEST TO 
REGULATE THE E-CIGARETTE AND ITS EFFECT ON SOCIETY’S YOUTH 
ADDISON J. MORGAN* 
INTRODUCTION 
Pursuant to the Food, Drug, and Cosmetic Act of 1938 (the “FDCA”), the Federal Drug 
Administration (the “FDA”) has possessed the power to regulate food, drugs, and cosmetic 
products for almost an entire century.1 The same cannot be said about tobacco products. Prior to 
2009, tobacco products were largely exempt from federal health and safety laws.2 Nonetheless, 
after the ratification of the Family Smoking Prevention and Tobacco Control Act of 2009, the FDA 
was granted the authority necessary to regulate tobacco products.3 Despite being the primary 
federal regulatory command with respect to tobacco, the FDA currently does not regulate the 
cigarette’s distant counterpart: the e-cigarette.4  
Since e-cigarettes were introduced into the United States in 2007, they have continuously 
become popular among adolescents.5 According to the Centers for Disease and Control (the 
“CDC”), high school student e-cigarette usage has increased by 78% since 2017 and that same 
usage has increased by 48% among middle schoolers.6 Moreover, in 2017, the e-cigarette market 
 
*J.D. Candidate, DePaul University College of Law, 2020; B.A. in Biology, Monmouth College, 2017. In the Fall of 
2020, Addison will begin his practice in the Consumer Financial Services Group at Ballard Spahr LLP in Minneapolis, 
Minnesota. Addison would like to thank his loving parents, Addison Morgan III and Dionne Morgan, for instilling in 
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1 See Federal Food, and Drug Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended at 21 
U.S.C. §§ 301-397 (1994 & Supp. II 1997)). 
2 See Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123 Stat. 1776 (2009). 
3 Id. 
4 See FOOD & DRUG ADMIN., MODIFICATIONS TO COMPLIANCE POLICY FOR CERTAIN DEEMED TOBACCO PRODUCTS, 
https://www.fda.gov/media/121384/download (last visited Apr. 19, 2019).  
5 Kristy Marynak et al., Exposure to Electronic Cigarette Advertising Among Middle School and High School 
Students – United States, 2014-2016, 67 MORBIDITY & MORTALITY WKLY. REP. 294, 298 (2018).   
6 Karen A. Cullen et al., Notes from the Field: Use of Electronic Cigarettes and any Tobacco Product Among 
Middle and High School Students – United States, 2011-2018, 67 MORBIDITY & MORTALITY WKLY. REP. 1276, 
1276 (2018). 
expanded by 40% to $1.16 billion.7 Majority of that economic growth is attributable to Juul, the 
United States’ most prominent vaporizer  manufacturer, whose vaping products have become quite 
appealing due to wide array of flavored e-cigarette liquid offered by the corporation.8 In response 
to the upward spike in adolescent e-cigarette usage, former FDA Commissioner Scott Gottlieb 
issued a statement in 2018 discussing the proposed policy framework he sought to advance to 
restrain youth appeal of e-cigarettes.9 Gottlieb’s proposed regulations would establish that all 
flavored e-cigarette products (i.e., e-liquids and cartridge-based systems) must be sold in age-
restricted, in-person locations to prevent underaged youth from accessing e-cigarette products 
online.10 
The ultimate objective of this article is to holistically assess the e-cigarette and its impact on 
society’s youth and evaluate the probable implications generated by the FDA’s proposed e-
cigarette regulations. In Part I, I will explore tobacco’s vast history within the United States by 
examining (1) the FDA’s legislative history, (2) the statute that purportedly authorized the agency 
to assert jurisdiction over tobacco products, and (3) modern case law that limits the FDA’s 
authoritative power to regulate tobacco products. In Part II, I will (1) examine the factors that have 
contributed to the swift increase in adolescent e-cigarette usage as well as the safety data that 
coincides with such usage, (2) analyze the FDA’s most recent e-cigarette regulations, and (3) 
ascertain whether those restrictions are sufficient to curb youth appeal.  
PART 1: HISTORICAL OVERVIEW OF THE FDA’S REGULATION OF TOBACCO 
 
7 Julia Belluz, FDA: we might have to ban some e-cigarettes to stop teens from vaping, VOX,  
https://www.vox.com/2018/9/12/17850598/fda-juul-vaping (last updated Sept. 21, 2018).   
 
8 Id. 
9 Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to address epidemic of youth e-cigarette 
use, FOOD & DRUG ADMIN. (Sept. 11, 2018), https://www.fda.gov/news-events/press-announcements/statement-fda-
commissioner-scott-gottlieb-md-new-steps-address-epidemic-youth-e-cigarette-use.   
10 Id. 
Although cigarettes and tobacco products alike may be revered by some, the health 
consequences engendered by tobacco usage have turned the lives of many Americans upside down. 
The injurious nature of tobacco cannot be overstated. Cigarettes are responsible for more than 
480,000 deaths per year in the United States and more than sixteen million Americans currently 
live with a disease caused by smoking.11 As each day passes, more than 3,200 youth younger than 
eighteen years of age smoke their first cigarette.12 Approximately 500,000 annual—albeit 
preventable—deaths is a mystifying number. Surely the government was cognizant of the 
multitude of health hazards associated with cigarette usage when Camel released an advertisement 
in 1937 contending that its cigarettes assisted digestion by increasing the movement of alkaline 
digestive fluids.13 Maybe it was aware, but then again, it is entirely plausible that the government 
was genuinely ignorant of tobacco’s wounding nature. Even so, in order for the FDA to create 
change and alter the cultural hegemony that, at the time, had completely inundated society with 
unproven proclamations and deceitful advertisements concerning cigarette side effects, the FDA 
needed unequivocal authoritative power.  
In 1938, Congress passed the FDCA.14 The FDCA provided the FDA with the power to 
regulate food, drugs, medical devices, and cosmetics.15 Specifically, the FDCA prohibits the “ . . . 
introduction or delivery for introduction into interstate commerce of any food, drug, device or 
cosmetic that is adulterated or misbranded.”16 The FDCA provided the FDA with an immense 
 
11 Smoking & Tobacco Use, CTR.S’ FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/index.htm?s_cid=osh-stu-home-spotlight-001 (last visited 
Nov. 17, 2019).  
12 Id. 
13 Cigarette Advertising Themes, STAN. UNIV. RES. INTO IMPACT TOBACCO ADVERT., 
http://tobacco.stanford.edu/tobacco_main/main.php (last visited Apr. 17, 2019).  
14 How did the Federal Food, Drug, and Cosmetic Act come about?, FOOD & DRUG ADMIN., 
https://www.fda.gov/about-fda/fda-basics/how-did-federal-food-drug-and-cosmetic-act-come-about (last visited 
Nov. 28, 2019).  
15 21 U.S.C. § 301(a) (1994 & Supp. II 1997). 
16 Id.  
amount of power to enforce the FDCA’s statutory provisions.17 For example, the district courts of 
the United States and the United States courts of the Territories have jurisdiction to issue 
injunctions if provisions within the FDCA are violated.18 Moreover, any person who violates any 
of the provisions enumerated in § 301 will be imprisoned for no more than a year or fined no more 
than $1,000—or both.19 Lastly, the FDA may seize any article of food, drug, or cosmetic that is 
adulterated or misbranded when such article is introduced, or discovered, in interstate commerce.20 
These seized articles are proceeded against on libel of information and condemned in any district 
court of the United States or United States court of a Territory within the jurisdiction where the 
article is found.21 This type of plenary power was not at the FDA’s disposal under the FDCA’s 
predecessor, the Food and Drug Act of 1906 (the “1906 Act”).22 The 1906 Act merely provided 
each district attorney with power to commence legal proceedings to enforce the penalties of the 
Act against parties who violated its provisions.23 Even so, the district attorney could only initiate 
legal proceedings provided that satisfactory evidence of any violation of the Act was presented to 
him or her by a health, food, or drug officer; or agent of any State, Territory, or the District of 
Columbia.24 Even though the enactment of the FDCA mitigated the administrative shortcomings 
of its predecessor and bestowed more authoritative power onto the FDA, the FDCA still possessed 
its own deficiencies. Under the FDCA, the FDA did not have the authority to explicitly regulate 
 
17 See id.  
18 See id. at §§ 302(a)-(b). 
19 Id. at § 303(a)(1). 
20 Id. at § 304(3)(A)(b). 
21 Id. at § 304(a)(1). 
22 Pure Food and Drug Act of 1906, Pub. L. No. 59-384, 34 Stat. 768 (codified as amended at 21 U.S.C. §§ 1-15 
(1934)). 
23 See id.  
24 Id. at § 5, 34 Stat. 769. 
tobacco and tobacco-related products.25 This deprivation of managerial control would become 
accentuated in the coming years as tobacco usage—–and tobacco harm—drastically increased.  
In light of the fact that many adolescents are introduced to cigarettes before their eighteenth 
birthday, the FDA decided to intervene and do something that the agency had not done before.26 
In August 1996, the FDA asserted jurisdiction—known as the FDA Rule of 1996—over cigarettes 
and smokeless tobacco under the Federal Food, Drug, and Cosmetic Act.27 The FDA proclaimed 
that it was permitted to assert jurisdiction over tobacco under the drug and device provisions of 
the FDCA for the following reason: 
“FDA has concluded that cigarettes and smokeless tobacco are combination 
products consisting of nicotine, a drug that causes addiction and other significant 
pharmacological effects on the human body, and device components that deliver 
nicotine to the body . . . . This evidence includes the emergence of a scientific 
consensus that cigarettes and smokeless tobacco cause addiction to nicotine and the 
disclosure of thousands of pages of internal tobacco company documents detailing 
that these products are intended by the manufacturers to affect the structure and 
function of the human body.28 
 
Pursuant to the FDCA, a product is a drug  if it is an article (other than food) “intended to affect 
the structure or any function of the body of man  . . . .”29 Consequently, it was this provision that 
catalyzed the FDA’s decision to devise a two-part conclusion explaining why it was permitted to 
assert jurisdiction over tobacco. 
 
25 Pursuant to the Federal Food, Drug, and Cosmetic Act, the FDA possessed the regulatory power to solely forbid 
the introduction of adulterated tobacco products into interstate commerce; See also 21 U.S.C. § 301(a).  
26 Youth and Tobacco, CTR.S’ FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/youth_data/tobacco_use/index.htm (last visited Nov. 17, 
2019).   
27 See Nicotine Is a Drug Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional Determination, 61 Fed. 
Reg. 44619, 45208 (Aug. 28, 1996). 
28 Id. at 44629. 
29 Federal Food, Drug, and Cosmetic Act § 201(g)(1)(C).  
First, the FDA asserted that nicotine in cigarettes and smokeless tobacco does “affect the 
structure or any function of the body.”30 The FDA’s contention was primarily based on nicotine’s 
pharmacological effect on the structure and function of the user’s body.31 Nicotine creates an 
addiction that induces repeated cigarette use merely to acquire more nicotine.32 Along with 
dependency and addiction, nicotine also impairs the user’s nervous system and accelerates loss of 
body weight.33 Because nicotine was analogous to drugs that the FDA had traditionally 
regulated—“including stimulants, tranquilizers, [and] appetite suppressants . . .”—the FDA argued 
that cigarettes and smokeless tobacco affected the “structure or any function of the body” within 
the meaning of the FDCA.34 
Second, the FDA asserted that the pharmacological effects generated by nicotine 
metabolization were “intended” by the tobacco manufacturers.35 “Intended use” refers to the 
objective intent of persons legally responsible for the labeling of drugs.36 Intent may be determined 
by such persons’ expressions or may be shown by the circumstances surrounding distribution of 
the article.37 Objective intent may be demonstrated by (1) labeling claims, (2) advertising matter, 
or (3) oral or written statements.38 The FDA posited that a substantial amount of evidence indicated 
that manufacturers intended for tobacco to affect the structure and function of the body: (1) the 
evidence of the foreseeable pharmacological effects and uses of cigarettes and smokeless tobacco; 
(2) the evidence of the actual consumer use of cigarettes and smokeless tobacco for 
 
30 Nicotine Is a Drug Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional Determination, 61 Fed. Reg. 
at 44629. 
31 Id. 
32 Nicotine Is a Drug Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional Determination, 61 Fed. Reg. 
at 44649. 
33 Id. at 44632. 
34 Id. 
35 Id. at 44686. 
36 See 21 C.F.R. § 201.128 (2019). 
37 Id. 
38 Id. 
pharmacological purposes; and (3) the evidence of the statements, research, and actions of the 
manufacturers themselves.39 Accordingly, because a robust, scientific consensus established that 
cigarettes and smokeless tobacco caused nicotine addiction and many tobacco manufacturers 
referred to nicotine as both “pharmacological agent[s]” and “extremely biologically active 
compound[s],” the FDA contended that cigarettes were “intended” by tobacco manufacturers to 
affect the structure and function of the body within the meaning of the FDCA.40 
The FDA’s assertion of jurisdiction over cigarettes and smokeless tobacco products was not 
premised on effectively banning nicotine.41 On the contrary, the FDA’s assertion of regulatory 
control was predicated on the fact that “tobacco use [had] become . . . one of the most serious 
public health problems facing the United States . . . .”42 Even though many states prohibited minors 
from purchasing tobacco, minors still possessed unfettered access to tobacco products via vending 
machines and over-the-counter sales.43 Based on these findings, the FDA promulgated a series of 
regulations cemented on two fundamental objectives: (1) restricting access and (2) redefining 
advertisements.44 The FDA sought to nullify the role marketing played in engraining the desire to 
smoke in the adolescent mind by restricting cigarette advertisements to a black and white, text-
only format.45 But if the advertisement appeared in a publication that was read almost exclusively 
by adults, the restriction was inapplicable.46 Marketing regulations also prohibited outdoor 
advertising within 1,000 feet of any public playground or school47; prohibited the distribution of 
 
39 Nicotine Is a Drug Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional Determination, 61 Fed. Reg. 
at 44687.  
40 Id. 
41 Id. 
42 Id. at 45428. 
43 Id. at 45244. 
44 Id. at 45243. 
45 See 21 C.F.R. § 897.32(a) (1996). 
46 Id. 
47 See 21 C.F.R. § 897.30(b) (1996).  
any promotional items, such as T-shirts or hats bearing the tobacco manufacturer’s brand name48; 
and prohibited tobacco manufacturers from sponsoring any athletic, musical, artistic, or cultural 
event using its brand name.49 Access regulations prohibited the distribution of cigarettes via 
vending machines; banned free samples; prohibited the sale of cigarettes to people under the age 
of eighteen; and required retailers to check photo identification before making a sale.50 The FDA 
presumably concluded that if the number of adolescents who begin tobacco use could be 
substantially diminished, then the prevalence of tobacco-related illness could be correspondingly 
reduced because scientific data suggested that anyone who did not begin smoking during their 
adolescent years was unlikely to ever begin.51 The FDA hoped that its assertion of jurisdiction and 
preliminary regulations would withstand a constitutional challenge. The livelihood of the FDA 
Rule of 1996 was contingent upon the United States Supreme Court’s interpretation of the FDCA 
in FDA v. Brown & Williamson. 
 
Modern Case Law Limiting the FDA’s Regulatory Authority 
 
In FDA v. Brown & Williamson, the Supreme Court of the United States was tasked with 
determining whether the FDA was permitted to regulate tobacco products according to the express 
language of the FDCA.52 The Court of Appeals for the Fourth Circuit held that Congress had not 
granted the FDA jurisdiction to regulate tobacco products.53 According to the Fourth Circuit, it 
 
48 See 21 C.F.R. § 897.34(a) (1996). 
49 See id. at § 897.34(c).  
50 See 21 C.F.R. § 897.14 (1996). 
51 Nicotine Is a Drug Under the Federal Food, Drug, and Cosmetic Act: Jurisdictional Determination, 61 Fed. Reg. 
at 45238. 
52 Food & Drug Admin. v. Brown & Williamson Tobacco Co., 120 S. Ct. 1291, 1297 (2000).  
53 Id. 
was impermissible for the FDA to assert jurisdiction over tobacco products because a number of 
provisions within the FDCA require the FDA to ascertain whether any regulated product is “safe” 
before it can be sold or allowed to remain on the market.54 Because the FDA had previously 
declared that tobacco products were “dangerous” and “unsafe,” the Fourth Circuit concluded that 
tobacco products could not be made safe and effective for their intended uses.55 Therefore, if 
tobacco products fell within the scope of the FDA’s jurisdiction, the FDA would be forced to 
remove tobacco products from the market immediately—a result that would be contrary to 
congressional intent.56 Consequently, the Fourth Circuit reasoned that tobacco regulation was 
forbidden under the FDCA’s present statutory framework.57 Surprisingly, before the FDA Rule of 
1996, the FDA had repeatedly disclosed that tobacco products fell outside the agency’s regulatory 
domain.58 
The Supreme Court affirmed the Fourth Circuit’s ruling and held that Congress had not given 
the FDA authority to assert jurisdiction over tobacco products.59 The Supreme Court based its 
holding on two concrete principles: (1) the FDCA’s core objective was to ensure that any product 
regulated by the FDA is “safe” and “effective” for its intended use60 and (2) Congress enacted 
tobacco-specific legislation against the backdrop of the FDA’s repeated statements that it lacked 
authority under the FDCA to regulate tobacco absent claims of therapeutic benefit by the 
manufacturer.61 Under the FDCA, the FDA shall prevent marketing of any drug or device where 




56 Id.; See also 7 U.S.C. § 1311(a) (2018) (repealed 2004). 
57 Williamson & Brown Tobacco Co., 120 S. Ct. at 1299. 
58 Id. 
59 Id. at 1315. 
60 Id. at 1301. 
61 Id. at 1306. 
benefit.”62 Additionally, for all devices regulated by the FDA, there must at least be a “reasonable 
assurance of the safety and effectiveness of the device.”63 In its 1996 Rule, the FDA described the 
adverse ramifications of tobacco usage in considerable detail, highlighting that “more than 400,000 
people die each year from tobacco-related illnesses such as cancer, respiratory illnesses, and heart 
disease, often suffering long and painful deaths . . . .”64 Because the FDA had continually 
acknowledged that “tobacco products are unsafe,” “dangerous,” and “cause great pain and 
suffering from illness,” it was statutorily impossible for the FDA to assert jurisdiction over tobacco 
products.65 Once the FDA concludes that a drug or device cannot be used safely for any therapeutic 
purpose, the FDA is barred from regulating such drug or device.66  
The FDCA expressly emphasizes that any product regulated by the FDA must be safe for its 
intended use.67 Although the FDA had determined that tobacco products are effective in 
transmitting specific pharmacological effects to its users, those products deliver such effects in an 
unsafe and dangerous manner.68 The Supreme Court decided that if tobacco products were within 
the FDA’s reach pursuant to the FDCA, then the FDCA would require the FDA to eradicate 
tobacco products entirely.69 But an indefinite ban on tobacco would contravene the tobacco-
specific regulatory scheme set in place by Congress to address tobacco and health.70 Thus, in the 
words of the Court, “[i]f [tobacco products] cannot be used safely for any therapeutic purpose, and 
 
62 Id. at 1301. 
63 21 U.S.C. § 393(b)(2)(C) (2018). 
64 Brown & Williamson Tobacco Corp., 120 S. Ct. at 1302.   
65 Id.  





yet [tobacco products] cannot be banned, [tobacco products] simply do not fit” within the confines 
of the FDA’s regulatory power pursuant to the Federal Food, Drug and Cosmetic Act.71 
After determining that the FDCA barred the FDA from exercising jurisdiction over tobacco 
products, the Court confirmed its holding by evaluating the tobacco-specific legislation that 
Congress had enacted.72 In response to the FDA’s proclamation that it lacked regulatory power, 
Congress sought to implement its own regulatory scheme for tobacco products by enacting the 
Alcohol and Drug Abuse Amendments in 1983, the Comprehensive Smoking Act in 1994, and the 
Comprehensive Smokeless Tobacco Health Education Act of 1986.73 Many of these laws 
precluded any administrative agency from playing a significant role in constructing tobacco 
policy.74 For example, the Alcohol and Drug Abuse Amendments required the Secretary of Health 
and Human Services to report directly to Congress every three years on the “addictive property of 
tobacco” and to include recommendations for action that the Secretary may deem appropriate.75 
The Supreme Court reasoned that Congress’s collective legislative action proscribed any 
interpretation of the FDCA that would empower the FDA to regulate tobacco products.76 Congress 
had developed a distinct regulatory scheme for the tobacco industry premised on the FDA’s 
inability to regulate tobacco products.77 Thus, Congress “effectively ratified the FDA’s previous 





73 Id. at 1311. 
74 Id. at 1313. 
75 Id. at 1311–12. 
76 Id. 
77 Id. 
78 Id. at 1313. 
 
The Family Smoking Prevention and Tobacco Control Act and the FDA’s “Deeming” Authority 
 
The Supreme Court’s decision in Brown v. Williamson invalidated the FDA’s 1996 Rule.79 
Accordingly, even in light of congressional action, cigarette smoking continued to generate serious 
illness resulting in approximately 440,000 annual deaths and $157 billion health-related economic 
costs.80 Nearly a decade after the Brown decision, President Barack Obama ratified the Family 
Smoking Prevention and Tobacco Control Act (“FSPTCA”), which gave the FDA sweeping 
authority to regulate the manufacturing, marketing, and sale of tobacco products.81 The FSPTCA’s 
predecessor, the FDCA, was premised on a public standard of “safety and efficacy.”82 Importantly, 
the FSPTCA departed from the FDCA’s traditional standard as the more recent statute enables the 
Secretary of Health and Human Services to regulate tobacco products in a manner that is 
“appropriate for the protection of the public health.”83 
The FSPTCA likely embodies a more hands-on, proactive standard because at the time the law 
was enacted, Congress was thoroughly aware of tobacco’s effect on the health of not only society’s 
adults—but its youth as well.84 Many adolescents are attracted to fruit assorted flavoring; therefore, 
the FSPTCA prohibits cigarettes from containing an artificial or natural flavor (other than tobacco 
or menthol), or an herb or spice, including “strawberry, grape, orange, clove, cinnamon, pineapple, 
vanilla, coconut, licorice, cocoa, chocolate, cherry, or coffee” that acts as characterizing flavor of 
 
79 Id. 
80 C. Husten et al., Cigarette Smoking Among Adults – United States, 2002, MORBIDITY & MORTALITY WKLY. REP. 
(May 28, 2004), https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5320a2.htm.  
81 Family Smoking Prevention and Tobacco Control Act § 910(a)-(c). 
82 Federal Food, Drug, and Cosmetic Act § 306(g)(1)(A)(I). 
83 Family Smoking Prevention and Tobacco Control Act § 907(a)(3)(A).  
84 Id. at § 2(14). 
the tobacco product or tobacco smoke.85 Furthermore, in an effort to combat public ignorance of 
tobacco and health, the FSPTCA discloses that it is illegal for cigarette packages to be sold, 
distributed, or imported for sale within the United States unless the package bears one of the labels 
enumerated within the statute.86 For example, one label reads, “WARNING: Smoking can kill 
you.”87 Although the FSPTCA authorized the FDA to promulgate certain marketing restrictions 
and to increase the visibility of tobacco warning labels, the FDA’s true power under the FSPTCA 
stems from its “deeming” authority.  
The statutory provision that effectuates the FDA’s “deeming” authority states as follows: “This 
chapter shall apply to all cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless 
tobacco and to any other tobacco products that the Secretary by regulation deems to be subject to 
this chapter.”88 Under the FSPTCA, a “tobacco product” is “any product made or derived from 
tobacco that is intended for human consumption, including any component, part, or accessory of a 
tobacco product (except for raw materials other than tobacco used in manufacturing a component, 
part, or accessory of a tobacco product).”89 In 2016, acting under the “deeming” provision of the 
FSPTCA, the FDA issued a final rule that extended the Agency’s “tobacco product” authority to 
all other categories of products that meet the FSPTCA’s definition of “tobacco.”90 According to 
the FDA, the terms “component” and “part” embedded in the FSPTCA’s “tobacco product” 
definition refer to “any software or assembly of materials intended or reasonably expected to (1) 
alter or affect the tobacco product’s performance, composition, constituents or characteristics; or 
 
85 Id. at § 907(a)(1)(A). 
86 Id. at § 201(a)(1). 
87 Id. 
88 Id. at § 901(b) (emphasis added). 
89 Id. at § 101(rr)(1). 
90 See Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, 81 Fed. Reg. 28974, 
28975 (2016). 
(2) to be used with or for the human consumption of a tobacco product.”91 These terms acted as 
regulatory hooks for the FDA, thereby expanding the FDA’s authoritative reach to components 
and parts used with electronic nicotine delivery systems (“ENDS”).92 Examples of ENDS 
components and parts that fall within the scope of the FDA’s regulatory command are e-cigarettes, 
E-liquids, atomizers, batteries and cartomizers.93 The FDA’s “deeming” authority begs the 
question: if the FDA has definite, unambiguous authority to ultimately subject any tobacco product 
to the provisions enumerated within the FSPTCA, why is adolescent e-cigarette usage at an all-
time high? 
 
PART II: A SPIKE IN ADOLESCENT E-CIGARETTE USAGE: A CAUSE FOR 
CONCERN 
 
Since 2011, e-cigarette usage has increased at an exponential rate; in 2014, e-cigarettes became 
the most commonly used tobacco among middle school and high school students.94 Specifically, 
in 2014, 16% of 10th graders reported use of e-cigarettes in the past 30 days and 43% of those 
students reported that he or she had never smoked a combustible cigarette.95 This statistic is 
unsettling because it undoubtedly exemplifies the rationale that encourages a vast majority of 
society’s youth to partake in e-cigarette usage: many adolescents—even those who have yet to 
smoke a Marlboro or Kool—adamantly believe that by smoking e-cigarettes, they are covertly 





94 Tushar Singh et al., Vital Signs: Exposure to Electronic Cigarette Advertising Among Middle School and High 
School Students – United States, 2014, 64 MORBIDITY & MORTALITY WKLY. REP. 1403, 1403–08 (2016). 
95 Adam M. Leventhal et al., Association of Electronic Cigarette Use with Initiation of Combustible Tobacco 
Product Smoking in Early Adolescence, 314 [J]AMA 700, 700–07 (2015).  
way in which an e-cigarette delivers nicotine to its user naturally induces curiosity in second-hand 
viewers. In a 2015 survey, e-cigarette consumers were asked to disclose the most important reason 
for utilizing the device.96 Tellingly, the response garnering the most submissions was “to 
experiment—to see what [e-cigarettes are] like.”97 Despite the fact that the decision to 
“experiment” with a device possessing such convoluted intricacies may indeed be a naive and 
uninformed one, should society’s youth themselves solely bear the blame for this uptick in e-
cigarette usage or should the blame be allocated to the FDA for failing to have the foresight 
necessary to prevent this phenomenon from occurring? The short answer: blame both.  
A. What is an e-cigarette and how is it mechanized? 
Electronic cigarettes are primarily battery-powered devices capable of delivering nicotine to 
its user in an aerosol form.98 When a user activates an e-cigarette, a metal coil is heated which in 
turn vaporizes a solution (i.e., e-liquid) mainly consisting of propylene glycol, vegetable glycerin, 
distilled water, and flavorings that frequently contain nicotine.99 This mechanism of action is 
colloquially referred to as “vaping” and nicotine, which is dissolved inside the e-liquid, is released 
in the aerosolized vapor produced by the heated coil inside the e-cigarette.100  
A combustible cigarette is mechanized in a drastically different fashion.101 Combustible 
cigarettes are activated by a process commonly known as “combustion.”102 Combustion requires 
 
96 LLOYD D. JOHNSTON ET AL., MONITORING THE FUTURE. NATIONAL SURVEY RESULTS ON DRUG USE 1975–2017. 
2017 OVERVIEW: KEY FINDINGS ON ADOLESCENT DRUG USE, https://files.eric.ed.gov/fulltext/ED589762.pdf (last 
visited Apr. 19, 2019). 
97 Id. 
98 Tushar Singh et al., supra note 94.  
99 Riccardo Polosa et al., Health Impact of E-cigarettes: A Prospective 3.5-year Study of Regular Daily Users who 
have Never Smoked, SCI. REPS., Nov. 17, 2017, at 1.   
100 Curtis C. Harris, Tobacco Smoking, E-cigarettes, and Nicotine Harm, 115 PROC. NAT’L. ACAD. SCI. U.S. 1406, 
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the user of the cigarette to ignite the end of the cigarette with fire.103 Once the cigarette is ignited, 
the combination of tobacco, fire, and oxygen induces a self-sustaining combustion process that 
continuously engulfs the tobacco.104 Principally, it is this combustion process that has prompted 
the substantial increase in adolescent e-cigarette usage over the years.105 From the layman’s 
perspective, combustible cigarettes create smoke and that smoke contains volatile components that 
induce fatal and debilitating health disorders.106 Because e-cigarette aerosols neither involve 
combustion nor tobacco smoke, adolescents have concluded that e-cigarettes are safer than 
combustible cigarettes.107 Notably, boundless empirical data exist substantiating the adolescent 
presumptive deduction: combustible cigarettes accounted for over 48% of all cancer-related deaths 
between 2005-2009 and cause more than 7 million deaths per year.108 Still, do the previous 
statistics definitively suggest that inhalation of aerosols emitted from e-cigarette devices are safer 
than the smoke emitted by a combustible cigarette? 
 
B. Are e-cigarettes safer than combustible cigarettes? 
 
Many e-cigarettes and all combustible cigarettes deliver nicotine to their respective users. 
Nicotine, a highly addictive chemical, has not been deemed carcinogenic in humans.109 Scientific 
studies suggest that combustible cigarette byproducts generate most of cigarette smoke’s harmful 
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health effects—primarily cancer.110 Therefore, the belief that the e-cigarette is a safer alternative 
must be assessed. It must be determined whether such belief is compelling or wholly conjectural.  
 
i. Combustible Cigarettes and Cancer 
 
Outside of nicotine, combustible cigarettes—via the smoke emitted—generate approximately 
7,000 toxic compounds and more than 70 identified carcinogens.111 At the moment the cigarette is 
ignited, the compounds present in the cigarette smoke undergo complex chemical reactions; the 
duration and extent of these chemical reactions is dependent upon the number of puffs taken by a 
user and puff duration.112 Both factors induce extreme variability in the number of toxins produced 
over the life of a single cigarette.113 The process that activates carcinogens in cigarette smoke is 
referred to as tobacco carcinogenesis.114 Despite the fact that cancer’s biological pathway remains 
an unfortunate mystery, tobacco carcinogenesis can be explained by examining rudimentary 
scientific principles. For cigarette smokers who develop cancer, cancer inception begins with 
nicotine as the substance’s addictive properties provoke an overindulgence in combustible 
cigarette usage.115 In turn, this progressively heightened usage of combustible cigarettes inundates 
the user’s body with an unfathomable number of carcinogens.116 As the carcinogens are 
metabolically activated, DNA adducts, which consists of carcinogen metabolites covalently 
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bonded to DNA, form.117 At this stage, DNA bound to carcinogens either (1) normalizes itself 
through enzymatic repair mechanisms (i.e., covalent bond between carcinogen and DNA is 
destroyed) or (2) the DNA adduct persists and carcinogenesis commences.118 This persistence may 
prompt genetic miscoding, which may ultimately result in a permanent mutation of DNA.119 
Chronic tobacco smokers unconsciously trigger this process an innumerable amount of times over 
the course of their lives and the potential for permanent, genetic mutations acutely increases as a 
result.120 
 
ii. Combustible Cigarettes and Cardiovascular Disease 
 
It is well-documented that combustible cigarette use is responsible for a variety of disorders 
including cardiovascular disease, which is the single largest cause of death in the United States, 
killing more than 800,000 people a year.121 Tobacco smoke is an independent risk factor of 
cardiovascular atherosclerosis.122 Atherosclerosis, the process by which the arteries narrow and 
become less flexible,123 has been conclusively linked to tobacco smoking.124 But the underlying 
causal nexus between tobacco smoke and atherosclerosis has not yet been discovered.125 On the 
surface, inhalation of tobacco smoke—even secondhand smoke—has the potential to directly 
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damage artery walls and severely impair endothelial function, thereby inhibiting vasodilation of 
normal coronary arteries and reducing coronary flow reserve.126 Moreover, combustible cigarettes 
have been associated with evidence of chronic inflammation127 of the arteries and this 
inflammatory response is a symptom of atherosclerosis.128 A number of studies have demonstrated 
that smoking causes a 20-25% increase in the peripheral blood leukocyte count and an increased 
level of inflammatory markers.129 Cigarette smoking leads to elevations of various 
proinflammatory cytokines and an increase in leukocyte-endothelial cell interaction which leads 
to leukocyte recruitment—an event triggered early on in the development of atherosclerosis. 
Tellingly, a study has documented that these inflammatory markers return to their baseline levels 
five years after smoking cessation; this not only indicates that cigarette-induced cardiovascular 
disease may be reversible, it also reveals that tobacco smoke is the primary trigger of inflammation 
in the blood and at the vessel wall.130  
 
iii. E-Cigarette Safety and the Renormalization of Smoking  
 
According to an independent evidence review published by Public Health England 
(“PHE”) in 2015, best estimates specify that “e-cigarettes are 95% less harmful to [one’s] health 
than [combustible] cigarettes, and when supported by a smoking cessation service, [e-cigarettes] 
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sensible; e-cigarettes deliver nicotine to its user in a manner that appears to circumvent the unstable 
combustion process that is responsible for subjecting conventional cigarette users to a plethora of 
ailments.132 Although PHE’s data seems to be commonsensical, the organization failed to proffer 
any legitimate scientific data substantiating its position and instead, the organization relied solely 
upon a single meeting of 12 people convened to develop a multicriteria decision analysis (MDCA) 
model to synthesize their opinions on the harms associated with different nicotine products.133  
Even though PHE’s evidence review was premised on inadequate methodological practices, 
PHE explicitly contended that “there is no evidence to date that [e-cigarettes] are [renormalizing] 
smoking . . . .”134 This assertion is utterly false on its face as it has been documented that e-
cigarettes became the most commonly used form of tobacco by middle school and high school 
students in 2014.135 Though PHE argued that the e-cigarette cannot be characterized as a gateway 
to combustible cigarettes, one American study arrived at a different conclusion suggesting that 
“[high school students] who used electronic cigarettes at baseline compared with non-user [high 
school students] were more likely to report initiation of combustible tobacco use over the next 
year.”136 Although safety data suggest that e-cigarettes contain lower levels of toxic substances 
than combustible cigarettes,137 the e-cigarette’s impact on society’s health is generally unknown.138 
Accordingly, speculative claims—like the proclamations made by PHE—run the risk of 
renormalizing smoking.139 “Renormalization” of smoking has the potential to render the potential 
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benefits that stem from e-cigarette usage irrelevant if, by and through such usage, society’s 
nicotine dependence increases by way of a restored approval of smoking in general.140  
E-cigarettes are extremely novel devices and that novelty evinces that it is irrefutably 
premature to support (let alone consciously disseminate) information purporting that e-cigarettes 
are categorically safer than combustible cigarettes. Recently, the FDA disclosed that e-cigarettes 
may be associated with seizures as the agency has received 35 reports of e-cigarette induced 
seizures since 2010.141 Moreover, vaping-related illnesses and deaths have proliferated out of thin 
air.142 Since the e-cigarette’s inception in 2007, the CDC and the FDA have reported six-vaping 
related deaths.143 Every single vaping-related death has occurred in 2019.144 Some of the deceased 
were young and completely healthy minutes before they were hospitalized for acute lung disease; 
others were old and frail.145 Health officials believe that vitamin E acetate—a chemical used 
primarily in cannabis-containing vaping products—is to blame.146 But neither the CDC nor the 
FDA have identified an explicit causal link between vaping and the preceding deaths.147 Yet, e-
cigarettes and its progeny remain on the market, flavorful and unregulated. At first glance, it seems 
pointless for these agencies to disclose such a small number of vaping-related seizures and deaths 
to the general public. But it is not the diminutive magnitude of the quantity of seizures and deaths 
that is alarming. On the contrary, it is the fact that such disclosure illuminates that the safety data 
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associated with e-cigarette usage is unresolved and inconclusive. As a result, an e-cigarette should 
be utilized in a fashion that mirrors the device’s present uncertainty. 
 
C. Who is truly at fault: the adolescents for making primarily uneducated decisions or the 
FDA for failing to regulate e-cigarettes? 
 
Even though it may be true that most adolescents who partake in recreational e-cigarette use 
do so without holistically assessing the consequences of that decision, it is also true that the FDA 
is obligated—by virtue that its existence is inextricably tied to protecting the public health—to 
inhibit the birth of such a decision. Presently, the FDA’s “deeming rule” prohibits e-cigarette 
retailers from (1) selling e-cigarettes to customers age 17 and younger;148 (2) distributing free 
samples; and (3) selling e-cigarettes in vending machines.149 On the other hand, e-cigarette 
manufacturers are solely prohibited from distributing free samples.150 Failure to comply with these 
regulations may render an e-cigarette adulterated, misbranded, or both, and it is unlawful for any 
entity to sell or distribute an adulterated and/or misbranded product in interstate commerce.151  
Clearly, the FDA has instituted express regulations to curb, not only youth appeal, but youth 
access to e-cigarettes. So, what’s the problem? Admittedly, the FDA has made major strides in the 
realm of e-cigarette regulation. Still, those strides do not overshadow or negate the fact that 
Congress effectuates laws for those laws to be fully complied with. All products and devices that 
the FDA has identified to be “tobacco products” pursuant to its “deeming” authority became 
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subject to the premarket authorization requirements of the FSPTCA as of August 8, 2016.152 
Premarket authorization requires that the product manufacturer receive FDA approval of its 
premarket approval application before the manufacturer markets the device.153 Before the FDA 
grants a manufacturer premarket approval for a product, the FDA assesses the validity of the 
scientific evidence associated with the manufacturer’s application to confirm that the proposed 
product is safe and effective for its intended use.154 In accordance with the FSPTCA, any 
manufacturer that seeks to introduce a tobacco product intended for human use into interstate 
commerce must first attain premarket authorization from the FDA.155 However, if the tobacco 
product that the manufacturer proposes to introduce into interstate commerce was commercially 
marketed in the United States prior to February 15, 2007 or the product is “substantially 
equivalent” to a product that has been previously granted premarket authorization by the FDA, 
then the FSPTCA’s premarket authorization requirements are inapplicable.156 Simply put, 
manufacturers of “new” tobacco products (i.e., products that were commercially marketed in 
interstate commerce after February 15, 2007) that have not received authorization to be introduced 
or delivered into interstate commerce via an FDA substantial equivalence order, must file a 
premarket authorization application with the FDA containing “full reports of all information . . . 
concerning investigations which have been made to show the health risks of such tobacco product 
. . . .”157  
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It has been documented that peer-reviewed toxicology information of the world’s leading e-
cigarette brands is extremely limited.158 Consequently, many, if not all, the premarket approval 
applications that would be submitted by manufacturers of “new” tobacco products would utterly 
fail to satisfy the requirement of informing the FDA of the “health risks” associated with such 
“new” tobacco products.159 Unsurprisingly, the scarcity of information concerning the health 
hazards triggered by e-cigarette usage should—conceivably—restrict a “new” tobacco product’s 
access to interstate commerce on account of the fact that its manufacturer cannot provide the FDA 
with the requisite information for premarket authorization. However, instead of transforming the 
preceding reasonable hypothesis into a reality by strictly enforcing § 910 of the FDCA, former 
FDA Commissioner Scott Gottlieb made an executive decision to allow “new” e-cigarettes to 
remain unconstrained on the market until August 8, 2021.160 After that date passes, the FDA has 
asserted that it “intends to prioritize enforcement for lack of a [premarket authorization] against 
flavored ENDS products.”161 Furthermore, the FDA has disclosed that its “decision to prioritize 
enforcement of [§ 910 of the FD&C Act] against a manufacturer and/or retailer will continue to 
be determined on a case-by-case basis.”162  
The FDA’s reasoning for effectively destroying the efficacy of the FDCA is that e-cigarettes 
have the potential to help adult smokers make the transition “completely off of combustible 
products.”163 This is undoubtedly a possibility; it is also entirely possible that the intrinsic 
properties of vitamin C may one day empower the nutrient to kill cancer.164 Regardless, this mere 
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possibility must be juxtaposed against the definitive fact that middle schoolers do not possess the 
intellectual wherewithal to properly evaluate the consequences—many of which are unknown165—
of partaking in recreational e-cigarette usage.166 Importantly, in 2013, it was documented that  61.1 
% of middle school and 80% of high school e-cigarette-using students reported that they smoked 
combustible cigarettes in conjunction with e-cigarettes.169 Conversely, 20.3% and 7.2% of students 
within those respective groups who documented that they had never smoked an e-cigarette 
similarly reported that they had never smoked a combustible cigarette either.170 The correlation 
between adolescent e-cigarette usage and adolescent combustible cigarette usage is uncomfortably 
astounding. The preceding data illustrates that youth who smoke e-cigarettes are inclined to smoke 
combustible cigarettes. On the other hand, if an adolescent is prohibited from “ripping” a Juul 
during his juvenile years, then it is highly unlikely—nearly theoretically impossible—that he will 
develop an e-cigarette-induced propensity to smoke Camels or Marlboros. Therefore, the FDA’s 
actions to date not only clearly defy the FSPTCA, but those actions also fail to sufficiently protect 
the health of the future citizenry of the United States.  
CONCLUSION 
In order to truly combat the epidemic rise in adolescent e-cigarette usage, the solution is quite 
simple. The FDA must earnestly enforce the FDCA and institute immediate regulations that firmly 
encroach upon the ability of society’s youth to obtain e-cigarettes. If the FDA continues to defer 
to e-cigarette manufacturers and retailers, misinformation will linger, deaths will inevitably ensue, 
and the health of youth nationwide will continue to progressively decline. Tellingly, the 
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unrestrained adolescent usage of e-cigarettes has prompted many states to enact statutes that place 
strict limitations on public e-cigarette consumption.171 The FDA must follow suit because if e-
cigarettes continue to be conspicuously utilized, then smoking behavior will be expeditiously 
destigmatized. Destigmatization of smoking will place future generations of youth at an intolerable 
disadvantage—a disadvantage that can ultimately be deemed null and void if the FDA’s 
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